72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers. (25th November 2018)

Record Type:: Journal Article
Title:: 72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers. (25th November 2018)
Main Title:: 72OAddition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
Authors:: Quintela-Fandino, M
Manso Sànchez, L M
Holgado Martín, E
Moreno, M C
Morales Murillo, S
Bermejo De Las Heras, B
Malon Gimenez, D
Colomer Bosch, R
Gonzalez Cortijo, L
Hornedo, J
Mouron, S
Muñoz, M
Escudero, S
Blanco, R
Mañes, S
Abstract:
Is Part Of:: Annals of oncology. Volume 29(2018)Supplement 9
Journal:: Annals of oncology
Issue:: Volume 29(2018)Supplement 9
Issue Display:: Volume 29, Issue 9 (2018)
Year:: 2018
Volume:: 29
Issue:: 9
Issue Sort Value:: 2018-0029-0009-0000
Page Start:
Page End:
Publication Date:: 2018-11-25
Subjects:: Oncology -- Periodicals
616.992
Journal URLs:: https://www.journals.elsevier.com/annals-of-oncology ↗
http://ukcatalogue.oup.com/ ↗
DOI:: 10.1093/annonc/mdy430.003 ↗
Languages:: English
ISSNs:: 0923-7534
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 1043.320000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:: 12261.xml